Tag: EU-AI-Act

2 articles

Policy & Regulation

China issues a medical-device standard for AI processing of EEG data in brain-computer interfaces

China's National Medical Products Administration (NMPA) has issued what state news agency Xinhua characterises as the world's first medical-device standard covering AI-processed electroencephalogram (EEG) data in brain-computer interfaces, announced on 14 September 2026. The standard was drafted by the National Institutes for Food and Drug Control (NIFDC) under an expedited procedure and becomes effective on 1 September 2027. Scope: quality requirements and evaluation methods for EEG datasets used by AI algorithms in BCI medical devices, covering collection, processing, annotation, storage, and access across R&D, production, and quality-control stages. Named NMPA and NIFDC officials: Yuan Peng (Deputy Director, NMPA Department of Medical Device Registration), Li Shu (Deputy Director, NIFDC medical device institute), Zheng Jia (Deputy Director, NIFDC Institute for Medical Device Standardization). This is the third BCI-related medical-device standard issued by China in twelve months, following 2025 standards on BCI terminology and on test methods for implantable closed-loop neural stimulators. The US FDA has no BCI-specific AI/EEG data-quality standard. The EU has no BCI-specific standard, only horizontal AI Act coverage of medical BCI as high-risk. On the narrow AI-EEG-BCI slice, China's world-first framing holds up.

Sep 17

Policy & Regulation

Germany's data protection commissioner presses Europe for tighter rules on bidirectional brain-computer interfaces

Prof. Dr. Louisa Specht-Riemenschneider, the outgoing German Federal Data Protection and Freedom of Information Commissioner (BfDI), used a BCI-themed academic conference at the University of Bonn on 4 September 2026 to press for tighter European handling of neural data. Her formal underpinning is a Berlin Group Working Paper on Emerging Neurotechnologies published on 15 May 2025 through BfDI, which invokes GDPR Article 9 (health and biometric data) and the EU AI Act (Article 5 subliminal-manipulation ban, Annex III high-risk classification for medical BCI) as existing legal ground. The intervention lands one month before Specht-Riemenschneider steps down for health reasons on 30 September 2026. Her Bundestag-elected successor Prof. Dr. Moritz Hennemann of Freiburg takes office on 1 October 2026, and his own position on neurodata is not publicly disclosed.

Sep 6